ArticleFunctional & integrative genomics2026
ALOX15 exerts tumor-suppressive role in head and neck squamous cell carcinoma via ERK pathway.
Article in Functional & integrative genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Arachidonate 15-Lipoxygenase (ALOX15) has been implicated in cellular homeostasis, yet its pan-cancer expression patterns, clinical relevance, and molecular mechanisms remain incompletely characterized. This study comprehensively analyzed ALOX15 expression across 33 cancer types using multi-omics data to evaluate its role in tumor progression, diagnostic potential, and therapeutic implications. We integrated resources from TCGA, GTEx, and other public databases to assess ALOX15 expression, mutational status, diagnostic value, prognostic significance, immune infiltration, and potential relevance to chemotherapy and immunotherapy. Results showed that ALOX15 was downregulated in multiple cancers, including head and neck squamous cell carcinoma (HNSC), but upregulated in others such as liver cancer. Its expression exhibited both positive and negative correlations with prognosis depending on cancer type. Immune infiltration analysis revealed significant associations between ALOX15 and levels of B cells, CD8⁺ T cells, dendritic cells, and M1 macrophages in most tumors. Pathway analysis indicated a close relationship between ALOX15 and the ERK signaling pathway. Experimental validation in HNSC clinical samples and cell lines demonstrated that low ALOX15 expression was correlated with clinicopathological parameters and identified as a protective factor. Functional assays showed that ALOX15 overexpression suppressed malignant behavior in cancer cells. Western blot analysis further confirmed that ALOX15 inhibits HNSC progression via the ERK pathway. In summary, ALOX15 may serve as a potential biomarker across multiple cancer types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.